Ogier Guernsey advises Stanley Capital on new investment structure and acquisition of Noden Pharma

Ogier's Guernsey team has assisted Stanley Capital with the establishment of a Guernsey investment structure and the acquisition of Noden Pharma DAC and Noden Pharma USA (Noden), a leading speciality pharmaceutical company.

The multi-disciplinary Ogier team worked with Stanley Capital, lead counsel Willkie Farr & Gallagher (London) LLP and alterDomus. The team was led by partner Bryon Rees and senior associate Michelle Watson Bunn, with support from partners Tim Clipstone and Bryan De Verneuil-Smith, senior associate Charlotte Brown and associate Henry Simpson.

Bryon Rees commented: "We are delighted to have supported Stanley Capital and its advisors on this new investment structure and the initial acquisition, creating a solid base for future growth into a leading pharma platform."

Noden is focused on providing unique, complex to manufacture prescription medicines for cardiovascular patients who are intolerant to mainstream treatments. It is the first acquisition and a core platform for implementing a strategy to consolidate the mature product speciality pharma marketplace. Stanley Capital, working alongside Noden's management team, will pursue a value investment philosophy, targeting the acquisition of multiple drug portfolios to create a differentiated and highly cash generative portfolio of attractive medicines with established operational, technical, or patent-led barriers to entry.

Simon Cottle, partner at Stanley Capital, said: “The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden’s excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions.”

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with enterprise values of $250mn to $2.5bn.